Eye Research Foundation | Newport Beach, CA

Research site

(Unclaimed)

Location

520 Superior Avenue, Suite 235, Newport Beach, California, United States of America

Site insights

Top conditions

Top treatments

Bimatoprost

Latanoprost

AR-15512

AMDX-2011P

AGN-195263

AGN-190584

Pilocarpine HCl

DE-117

RVL-1201

KPI-121

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 69 total trials

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibo...

Enrolling

Dry Eye Disease

Other: Vehicle

Drug: AZR-MD-001

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Not yet enrolling

Open-angle Glaucoma

Ocular Hypertension

Drug: Bimatoprost Ophthalmic Solution, 0.01%

Drug: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

New

A Study of AMDX-2011P in Participants With Alzheimer's Disease

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling

Alzheimer Disease

Drug: AMDX-2011P

A Study of AMDX-2011P in Participants With CAA

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling

Cerebral Amyloid Angiopathy

Drug: AMDX-2011P

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Op...

Enrolling

Primary Open Angle Glaucoma

Drug: AMDX-2011P

AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy (PROBE)

The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational re...

Enrolling

Parkinson Disease

Amyotrophic Lateral Sclerosis

Drug: AMDX2011P

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in...

Enrolling

Open Angle Glaucoma

Ocular Hypertension

Drug: Latanoprost 0.005%

Drug: NCX 470 0.1%

Next Generation Rocklatan

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Begins enrollment in 1 month

Open Angle Glaucoma

Ocular Hypertension

Drug: AR-17043 Ophthalmic Solution

Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure (TC-002-301)

Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive ef...

Active, not recruiting

Elevated Intraocular Pressure

Drug: TC-002 latanoprost ophthalmic solution, 0.005%

Drug: Latanoprost ophthalmic solution, 0.005%

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult...

Active, not recruiting

Dry Eye

Meibomian Gland Dysfunction

Device: TearCare System

Drug: Restasis